![]() ![]() ![]() Generating significant cash flow to support a prudent capital allocation strategy, andĭeploying capital for strategic acquisitions delivering topline and margin expansion.īio-Rad’s two highly complementary business segments, Life Science Research and Clinical Diagnostics, are focused on large addressable markets with attractive growth characteristics. Optimizing cost structure and aligning the organization with the most promising growth opportunities,Īchieving improved operating efficiencies and enabling greater operating leverage, We are also introducing new products and capabilities, with an expanded suite of ddPCR TM products, initial offerings in single cell analysis, and molecular diagnostics.”Ĭompany presentations will provide greater insight into Bio-Rad’s strategy and objectives, including:Īccelerating revenue growth through ongoing portfolio transformation, increased focus in biopharma, and key product franchises, Laying the groundwork for accelerated growth and improved profitability, we are continuing to expand our global footprint, customer base and product portfolio. Our leadership team is embarking on the next phase of our transformation and we are well-positioned to achieve the new financial targets for 2025. Norman Schwartz, Bio-Rad’s Chief Executive Officer, commented: “Having exceeded all of the long-term financial targets we outlined in 2017, we are now excited to share the details of our growth strategy and how we are poised to enhance our financial profile even further. We define core revenue as currency neutral non-GAAP revenue and excludes COVID-related sales. For 2025, the Company expects to enhance its financial profile even further, targeting about 9% core revenue CAGR from 2021 to 2025, and 28% adjusted EBITDA margin in 2025. During the event, members of Bio-Rad’s executive leadership team will provide an in-depth overview of the Company’s growth strategy and new long-term financial targets, as well a closer look at the drivers within the two core business segments – Life Science Research and Clinical Diagnostics.ĭuring its investor day in 2017, Bio-Rad stated a target revenue growth range of 3-5%, and an adjusted EBITDA margin target of 20%+ in 2020, both of which the Company exceeded. ![]() (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |